Investigation Report on Chinese Thymosin α1 Market, 2018-2022

According to CRI, Thymosin α1 has been growing since it entered China, with its sales value increasing from less than CNY 7 million in 2015 to more than CNY 1.2 billion in 2017.

Reference: 1807303
Price: $2,200.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
July 2018
Pages
30
Version:
2018
Charts:
20
Language
  • English
  • Chinese
Format
License

Description

Thymosins can enhance body immunity and are mainly used in the treatment of hepatitis and tumors. Thymosins mainly include Thymosin, Thymopentin and Thymosin α1. Thymosin α1 is a high-end thymosin.

It was first launched in the U.S. as an immunomodulator for tumor immnuotherapy. Now it has been clinically used in the treatment of many tumors. Research shows that the use of Thymosin α1 in tumor chemotherapy and radiotherapy can enhance patients' immunity, reduce toxic side effects and infection rate, improve patients' life quality, and increase remission rate and even survival rate. As a vaccine adjuvant, Thymosin α1 can enhance the immune response to viral vaccines such as influenza and hepatitis B vaccines for people with impaired or inhibited immune functions including patients who are receiving chronic hemodialysis and suffering from geriatric diseases.

According to CRI, Thymosin α1 has been growing since it entered China, with its sales value increasing from less than CNY 7 million in 2015 to more than CNY 1.2 billion in 2017. The Chinese Thymosin α1 market is now dominated by the products of Patheon, Hainan Shuangcheng Pharmaceuticals Co., Ltd., Chengdu DIAO Jiuhong Pharmaceutical Factory, etc. By sales value, Patheon captured more than half of the market, becoming the most powerful market player in 2017. By sales volume, Chengdu DIAO Jiuhong Pharmaceutical Factory took up the largest market share. Many domestic enterprises seek to scrabble for market shares from Patheon by advantage of low prices.

According to CRI, the incidence of cancer is increasing with the economic development, aggravating environmental pollution and residents' changing lifestyle. Therefore, the Thymosin α1 market will continue to grow from 2018 to 2022 as the immunomodulator market grows gradually.

 

Topics Covered

-Size of Chinese Thymosin α1 market

-Competition pattern of the Chinese Thymosin α1 market

- Prices in the Chinese Thymosin α1 market

-Prospects of the Chinese Thymosin α1 market

 

Table of Contents

1 Relevant Concepts of Thymosin α1

1.1 Indications for Thymosin α1

1.2 Development History of Thymosin α1 in China

1.3 Production Permit of Thymosin α1 in China

 

2 Investigation on Sales of Thymosin α1 in China, 2013-2017

2.1 Sales Value of Thymosin α1 in China, 2013-2017

2.1.1 Overall Sales Value

2.1.2 Sales Value in Key Regions of China

2.2 Sales Volume of Thymosin α1 in China, 2013-2017

2.2.1 Overall Sales Volume

2.2.2 Sales Volume in Key Regions of China

2.3 Dosage Forms of Thymosin α1 in China

 

3 Market Shares of Major Thymosin α1 Manufacturers in China

3.1 Market Shares of Major Thymosin α1 Manufacturers

3.1.1 Market Shares by Sales Value

3.1.2 Market Shares by Sales Volume

3.2 Patheon N.V.

3.3 Chengdu DIAO Jiuhong Pharmaceutical Factory

3.3.1 Profile of Chengdu DIAO Jiuhong Pharmaceutical Factory

3.3.2 Sales of Chengdu DIAO Jiuhong Pharmaceutical Factory's Thymosin α1

 (The structures of 3.4-3.9 are similar with that of 3.3.)

3.4 Hainan Shuangcheng Pharmaceuticals Co., Ltd.

3.5 Hainan Zhonghe Pharmaceutical Co., Ltd.

3.6 SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.

3.7 Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.

3.8 Chengdu Shengnuo Biopharm Co., Ltd.

3.9 Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.

 

4 Prices of Thymosin α1 in China, 2017-2018

4.1 Analysis on Average Price of Thymosin α1 in China

4.2 Prices of Thymosin α1 of Major Enterprises

4.2.1 Patheon (Trade Name: Zadaxin)

4.2.2 Chengdu DIAO Jiuhong Pharmaceutical Factory (Trade Name: Maipuxin)

4.2.3 Hainan Shuangcheng Pharmaceuticals Co., Ltd. (Trade Name: Jitai)

4.2.4 Hainan Zhonghe Pharmaceutical Co., Ltd. (Trade Name: Heri)

4.2.5 SPH No. 1 Biochemical & Pharmaceutical Co., Ltd. (Trade Name: Xingtuokang)

4.2.6 Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. (Trade Name: Liding)

4.2.7 Chengdu Shengnuo Biopharm Co., Ltd. (Trade Name: Xinnuoli)

4.2.8 Harbin Pharmaceutical Group Bio-Engineering Co., Ltd. (Trade Name: Tailuoting)

 

5 Prospects of Chinese Thymosin α1 Market, 2018-2022

5.1 Forecast on Market Size

5.2 Forecast on Competition Pattern

 

Selected Charts

Chart Production Permit of Thymosin α1 in China

Chart Sales of Thymosin α1 in China, 2013-2017

Chart Sales Value of Thymosin α1 in China, 2013-2017

Chart Sales Value of Thymosin α1 in Parts of China, 2013-2017

Chart Sales Volume of Thymosin α1 in China, 2013-2017

Chart Market Shares of Top 5 Thymosin α1 Manufacturers by Sales Value, 2013-2017

Chart Market Share and Sales Value of Patheon Italia (IT)'s Thymopentin α1 in China, 2013-2017

Chart Market Share and Sales Value of DIAO Jiuhong's Thymopentin α1 in China, 2013-2017

Chart Prices of Patheon's Thymopentin α1 in Several Chinese Cities, 2017-2018

Chart Prices of SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.'s Thymopentin α1 in Several Chinese Cities, 2017-2018

Chart Prices of Chengdu DIAO Jiuhong Pharmaceutical Factory's Thymopentin α1 in Several Chinese Cities, 2017-2018

Chart Forecast on Thymopentin's Sales in China, 2018-2022

 

Scroll